Current clinical perspectives on myocardial angiogenesis

Molecular and Cellular Biochemistry

Volumn 264, Issue 1-2, 2004, Pages 157-167

  Mukherjee, Debabrata ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Angiogenesis; Cell transplantation; Coronary artery disease; Growth factors

Indexed keywords

ACETYLSALICYLIC ACID; ACIDIC FIBROBLAST GROWTH FACTOR; ADENOVIRUS VECTOR; ANGIOGENIC FACTOR; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 4; FIBROBLAST GROWTH FACTOR 5; GLYCERYL TRINITRATE; HYPOXIA INDUCIBLE FACTOR 1; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMID DNA; PLATELET DERIVED GROWTH FACTOR; RECOMBINANT SCATTER FACTOR; SCATTER FACTOR; SPIRONOLACTONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN 121; VASCULOTROPIN 165; VASCULOTROPIN A; VASCULOTROPIN C;

ACUTE HEART INFARCTION; ANGIOGENESIS; ANGIOMA; ATHEROSCLEROSIS; BYPASS SURGERY; CANCER; CARDIOVASCULAR RISK; CELL TRANSPLANTATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIABETIC RETINOPATHY; DISEASE SEVERITY; GENE DELIVERY SYSTEM; GENE THERAPY; GENE TRANSFER; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HEART TRANSPLANTATION; HUMAN; HYPOTENSION; MORTALITY; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL EDEMA; PROTEIN EXPRESSION; PROTEINURIA; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SYMPTOMATOLOGY; THROMBOCYTOPENIA; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

ANIMALS; CELL TRANSPLANTATION; CORONARY DISEASE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GROWTH SUBSTANCES; HUMANS; MYOCARDIAL ISCHEMIA; MYOCARDIAL REVASCULARIZATION; NEOVASCULARIZATION, PHYSIOLOGIC; TIME FACTORS;

EID: 5544322203     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:MCBI.0000044385.55012.8f     Document Type: Review

References (72)

1. Mukherjee D, Bhatt DL, Roe MT, Patel V, Ellis SG: Direct myocardial revascularization and angiogenesis - How many patients might be eligible? Am J Cardiol 84: 598-600, 1999
2. American Heart Association: 2002 Heart and Stroke Statistical Update, 2002
3. Mukherjee D, Comella K, Bhatt DL, Roe MT, Patel V, Ellis SG: Clinical outcome of a cohort of patients eligible for therapeutic angiogenesis or transmyocardial revascularization. Am Heart J 142: 72-74, 2001
4. Silvestre JS, Kamsu-Kom N, Clergue M, Duriez M, Levy BI: Very-low-dose combination of the angiotensin-converting enzyme inhibitor perindopril and the diuretic indapamide induces an early and sustained increase in neovascularization in rat ischemic legs. J Pharmacol Exp Ther 303: 1038-1043, 2002
5. Mukherjee D, Ellis SG: New options for untreatable coronary artery disease: Angiogenesis and laser revascularization. Cleve Clin J Med 67: 577-583, 2000
6. Tamirisa KP, Mukherjee D: Gene therapy in cardiovascular diseases. Curr Gene Ther 2: 427-435, 2002
7. Yla-Herttuala S, Martin JF: Cardiovascular gene therapy. Lancet 355: 213-222, 2000
8. Isner JM: Myocardial gene therapy. Nature 415: 234-239, 2002
9. Symes J: Gene therapy for ischemic heart disease: Therapeutic potential. Am J Cardiovasc Drugs 1: 159-166, 2001
10. Schratzberger P, Tkebuchava T, Kirchmair R, Milliken C, Bahlmann F, Tepper, Kawamoto A, Iwaguro H, Pola R, Zuk R, Brisken A, Vale P, Isner J: Ultrasound enhances therapeutic gene expression in ischemic pig myocardium. J Am Coll Cardiol 37: 266A, 2001
11. Mukherjee D, Wong J, Griffin B, Ellis SG, Porter T, Sen S, Thomas JD: Ten-fold augmentation of endothelial uptake of vascular endothelial growth factor with ultrasound after systemic administration. J Am Coll Cardiol 35: 1678-1686, 2000
12. Zhou Z, Mukherjee D, Wang K, Zhou X, Tarakji K, Ellis K, Chan A, Penn M, Ostensen J, Thomas J, Garcia M, Topol E, Ellis S: Induction of angiogenesis in a Canine model of chronic myocardial ischemia with intravenous infusion of vascular endothelial growth factor (VEGF) combined with ultrasound energy and echo contrast agent. J Am Coll Cardiol 39: 396A, 2002
13. Symes JF, Losordo DW, Vale PR, Lathi KG, Esakof DD, Mayskiy M, Isner JM: Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann Thorac Surg 68: 830-836, 1999
14. Fortuin F, Vale P, Losordo D, DeLaria G, Tyner J, Symes J, Schaer G, Lopez J, Van Camp J, Henry T, Richenbacher W, Rogers J, Isner J, Schatz R: Direct myocardial gene transfer of vascular endothelial growth factor-2 (VEGF-2) naked DNA via thoracotomy relieves angina pectoris and increases exercise time: One-year follow-up of a completed dose. J Am Coll Cardiol 37: 285A, 2001
15. Vale PR, Losordo DW, Milliken CE, Maysky M, Esakof DD, Symes JF, Isner JM: Left ventricular electromechanical mapping to assess efficacy of ph VEGF (165) gene transfer for therapeutic angiogenesis in chronic myocardial ischemia. Circulation 102: 965-974, 2000
16. Henry T, Rocha-Singh K, Isner J, Keriakes D, Giordano F, Simons M: Results of intracoronary recombinant human vascular endothelial growth factor (rhVEGF) administration trial. J Am Coll Cardiol 31: 65A, 1998
17. Losordo DW, Vale PR, Symes JF, Dunnington CH, Esakof DD, Maysky M, Ashare AB, Lathi K, Isner JM: Gene therapy for myocardial angiogenesis: Initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 98: 2800-2804, 1998
18. Losordo DW, Vale PR, Isner JM: Gene therapy for myocardial angiogenesis. Am Heart J 138: S132-S141, 1999
19. Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ, Shah PK, Willerson JT, Benza RL, Berman DS, Gibson CM, Bajamonde A, Rundle AC, Fine J, McCluskey ER: The VIVA trial: Vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 107: 1359-1365, 2003
20. Rosengart TK, Lee LY, Patel SR, Sanborn TA, Parikh M, Bergman GW, Hachamovitch R, Szulc M, Kligfield PD, Okin PM, Hahn RT, Devereux RB, Post MR, Hackett NR, Foster T, Grasso TM, Lesser ML, Isom OW, Crystal RG: Angiogenesis gene therapy: Phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 100: 468-474 1999
21. Rosengart TK, Lee LY, Patel SR, Kligfield PD, Okin PM, Hackett NR, Isom OW, Crystal RG: Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA. Ann Surg 230: 466-470; discussion 470-462, 1999
22. Pu LQ, Sniderman AD, Brassard R, Lachapelle KJ, Graham AM, Lisbona R, Symes JF: Enhanced revascularization of the ischemic limb by angiogenic therapy. Circulation 88: 208-215, 1993
23. Giordano FJ, Ping P, McKirnan MD, Nozaki S, DeMaria AN, Dillmann WH, Mathieu-Costello O, Hammond HK: Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat Med 2: 534-539, 1996
24. Safi J, Jr., Gloe TR, Riccioni T, Kovesdi I, Capogrossi MC: Gene therapy with angiogenic factors: A new potential approach to the treatment of ischemic diseases. J Mol Cell Cardiol 29: 2311-2325, 1997
25. Laham RJ, Sellke FW, Edelman ER, Pearlman JD, Ware JA, Brown DL, Gold JP, Simons M: Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: Results of a phase I randomized, double-blind, placebo-controlled trial. Circulation 100: 1865-1871, 1999
26. Sellke FW, Laham RJ, Edelman ER, Pearlman JD, Simons M: Therapeutic angiogenesis with basic fibroblast growth factor: Technique and early results. Ann Thorac Surg 65: 1540-1544, 1998
27. Udelson JE, Dilsizian V, Laham RJ, Chronos N, Vansant J, Blais M, Galt JR, Pike M, Yoshizawa C, Simons M: Therapeutic angiogenesis with recombinant fibroblast growth factor-2 improves stress and rest myocardial perfusion abnormalities in patients with severe symptomatic chronic coronary artery disease. Circulation 102: 1605-1610, 2000
28. Schumacher B, Pecher P, von Specht BU, Stegmann T: Induction of neoangiogenesis in ischemic myocardium by human growth factors: First clinical results of a new treatment of coronary heart disease. Circulation 97: 645-650, 1998
29. Simons M, Annex BH, Laham RJ, Kleiman N, Henry T, Dauerman H, Udelson JE, Gervino EV, Pike M, Whitehouse MJ, Moon T, Chronos NA: Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: Double-blind, randomized, controlled clinical trial. Circulation 105: 788-793, 2002
30. Grines CL, Watkins MW, Helmer G, Penny W, Brinker J, Marmur JD, West A, Rade JJ, Marrott P, Hammond HK, Engler RL: Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 105: 1291-1297, 2002
31. Vanbelle E., Maillard L., Tio FO, Isner JM: Scatter factor stimulates angiogenesis in a rabbit model of hindlimb ischemia. Circulation. 92: 78, 1995
32. Shyu KG, Manor O, Magner M, Yancopoulos GD, Isner JM: Direct intramuscular injection of plasmid DNA encoding angiopoietin-1 but not angiopoietin-2 augments revascularization in the rabbit ischemic hindlimb. Circulation 98: 2081-2087, 1998
33. Vincent KA, Shyu KG, Luo Y, Magner M, Tio RA, Jiang C, Goldberg MA, Akita GY, Gregory RJ, Isner JM: Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1alpha/VP16 hybrid transcription factor. Circulation 102: 2255-2261, 2000
34. Martins RN, Chleboun JO, Sellers P, Sleigh M, Muir J: The role of PDGF-BB on the development of the collateral circulation after acute arterial occlusion. Growth Factors 10: 299-306, 1994
35. Inoue M, Itoh H, Ueda M, Naruko T, Kojima A, Komatsu R, Doi K, Ogawa Y, Tamura N, Takaya K, Igaki T, Yamashita J, Chun TH, Masatsugu K, Becker AE, Nakao K: Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: Possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation 98: 2108-2116, 1998
36. Pollman MJ, Hall JL, Mann MJ, Zhang L, Gibbons GH: Inhibition of neointimal cell bcl-x expression induces apoptosis and regression of vascular disease. Nat Med 4: 222-227, 1998
37. Indolfi C, Avvedimento EV, Rapacciuolo A, Di Lorenzo E, Esposito G, Stabile E, Feliciello A, Mele E, Giuliano P, Condorelli G, et al.: Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo. Nat Med 1: 541-545, 1995
38. Hart CE, Kraiss LW, Vergel S, Gilbertson D, Kenagy R, Kirkman T, Crandall DL, Tickle S, Finney H, Yarranton G, Clowes AW: PDGF-beta receptor blockade inhibits intimal hyperplasia in the baboon. Circulation 99: 564-569, 1999
39. van der Zee R, Murohara T, Luo Z, Zollmann F, Passeri J, Lekutat C, Isner JM: Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium. Circulation 95: 1030-1037, 1997
40. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R: A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346: 1773-1780, 2002
41. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, Dudek D, Fort S, Schiele F, Zmudka K, Guagliumi G, Russell ME: Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 108: 788-794, 2003
42. Shah AS, White DC, Emani S, Kypson AP, Lilly RE, Wilson K, Glower DD, Lefkowitz RJ, Koch WJ: In vivo ventricular gene delivery of a beta-adrenergic receptor kinase inhibitor to the failing heart reverses cardiac dysfunction. Circulation 103: 1311-1316, 2001
43. Schmidt U, Hajjar RJ, Helm PA, Kim CS, Doye AA, Gwathmey JK: Contribution of abnormal sarcoplasmic reticulum ATPase activity to systolic and diastolic dysfunction in human heart failure. J Mol Cell Cardiol 30: 1929-1937, 1998
44. Miyamoto MI, del Monte F, Schmidt U, DiSalvo TS, Kang ZB, Matsui T, Guerrero JL, Gwathmey JK, Rosenzweig A, Hajjar RJ: Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. Proc Natl Acad Sci USA 97: 793-798, 2000
45. 2+ ATPase gene in the heart of transgenic mice accelerates calcium transients and cardiac relaxation. J Clin Invest 100: 380-389, 1997
46. Maurice JP, Hata JA, Shah AS, White DC, McDonald PH, Dolber PC, Wilson KH, Lefkowitz RJ, Glower DD, Koch WJ: Enhancement of cardiac function after adenoviral-mediated in vivo intracoronary beta2-adrenergic receptor gene delivery. J Clin Invest 104: 21-29, 1999
47. Weig HJ, Laugwitz KL, Moretti A, Kronsbein K, Stadele C, Bruning S, Seyfarth M, Brill T, Schomig A, Ungerer M: Enhanced cardiac contractility after gene transfer of V2 vasopressin receptors in vivo by ultrasound-graded injection or transcoronary delivery. Circulation 101: 1578-1585, 2000
48. Reinlib L, Field L: Cell transplantation as future therapy for cardiovascular disease? A Workshop of the National Heart, Lung, and Blood Institute. Circulation 101: E182-E187, 2000
49. Sakai T, Li RK, Weisel RD, Mickle DA, Jia ZQ, Tomita S, Kim EJ, Yau TM: Fetal cell transplantation: A comparison of three cell types. J Thorac Cardiovasc Surg 118: 715-724, 1999
50. Menasche P, Hagege AA, Scorsin M, Pouzet B, Desnos M, Duboc D, Schwartz K, Vilquin JT, Marolleau JP: Myoblast transplantation for heart failure. Lancet 357: 279-280, 2001
51. Murry CE, Wiseman RW, Schwartz SM, Hauschka SD: Skeletal myoblast transplantation for repair of myocardial necrosis. J Clin Invest 98: 2512-2523, 1996
52. Scorsin M, Hagege A, Vilquin JT, Fiszman M, Marotte F, Samuel JL, Rappaport L, Schwartz K, Menasche P: Comparison of the effects of fetal cardiomyocyte and skeletal myoblast transplantation on postinfarction left ventricular function. J Thorac Cardiovasc Surg 119: 1169-1175, 2000
53. Koh GY, Klug MG, Soonpaa MH, Field LJ: Differentiation and long-term survival of C2C12 myoblast grafts in heart. J Clin Invest 92: 1548-1554, 1993
54. Koh GY, Kim SJ, Klug MG, Park K, Soonpaa MH, Field LJ: Targeted expression of transforming growth factor-beta 1 in intracardiac grafts promotes vascular endothelial cell DNA synthesis. J Clin Invest 95: 114-121, 1995
55. Li RK, Jia ZQ, Weisel RD, Merante F, Mickle DA: Smooth muscle cell transplantation into myocardial scar tissue improves heart function. J Mol Cell Cardiol 31: 513-522, 1999
56. Li RK, Weisel RD, Mickle DA, Jia ZQ, Kim EJ, Sakai T, Tomita S, Schwartz L, Iwanochko M, Husain M, Cusimano RJ, Burns RJ, Yau TM: Autologous porcine heart cell transplantation improved heart function after a myocardial infarction. J Thorac Cardiovasc Surg 119: 62-68, 2000
57. Marelli D, Desrosiers C, el-Alfy M, Kao RL, Chin RC: Cell transplantation for myocardial repair: An experimental approach. Cell Transplant 1: 383-390, 1992
58. Rajnoch C, Chachques JC, Berrebi A, Bruneval P, Benoit MO, Carpentier A: Cellular therapy reverses myocardial dysfunction. J Thorac Cardiovasc Surg 121: 871-878, 2001
59. Taylor DA, Atkins BZ, Hungspreugs P, Jones TR, Reedy MC, Hutcheson KA, Glower DD, Kraus WE: RegeneratIng functional myocardium: improved performance after skeletal myoblast transplantation. Nat Med 4: 929-933, 1998
60. Kocher AA, Schuster MD, Szabolcs MJ, Takuma S, Burkhoff D, Wang J, Homma S, Edwards NM, Itescu S: Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 7: 430-436, 2001
61. Tomita S, Li RK, Weisel RD, Mickle DA, Kim EJ, Sakai T, Jia ZQ: Autologous transplantation of bone marrow cells improves damaged heart function. Circulation 100: II247-II256, 1999
62. Jackson KA, Majka SM, Wang H, Pocius J, Hartley CJ, Majesky MW, Entman ML, Michael LH, Hirschi KK, Goodell MA: Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. J Clin Invest 107: 1395-1402, 2001
63. Beltrami AP, Urbanek K, Kajstura J, Yan SM, Finato N, Bussani R, Nadal-Ginard B, Silvestri F, Leri A, Beltrami CA, Anversa P: Evidence that human cardiac myocytes divide after myocardial infarction. N Engl J Med 344: 1750-1757, 2001
64. Shintani S, Murohara T, Ikeda H, Ueno T, Honma T, Katoh A, Sasaki K, Shimada T, Oike Y, Imaizumi T: Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation 103: 2776-2779, 2001
65. Yau T, Zung K: Enhanced myocardial angiogenesis by gene transfer using transplanted cells. Circulation 102: II-682, 2000
66. Askari AT, Unzek S, Popovic ZB, Goldman CK, Forudi F, Kiedrowski M, Rovner A, Ellis SG, Thomas JD, DiCorleto PE, Topol EJ, Penn MS: Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet 362: 697-703, 2003
67. Hamano K, Li TS, Kobayashi T, Hirata K, Yano M, Kohno M, Matsuzaki M: Therapeutic angiogenesis induced by local autologous bone marrow cell implantation. Ann Thorac Surg 73: 1210-1215, 2002
68. Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann M, Rutten H, Fichtlscherer S, Martin H, Zeiher AM: HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 108: 391-397, 2001
69. Chande M: Stem cells get to the heart of the matter. Lancet 357: 1099, 2001
70. Penn MS, Francis GS, Ellis SG, Young JB, McCarthy PM, Topol EJ: Autologous cell transplantation for the treatment of damaged myocardium. Prog Cardiovasc Dis 45: 21-32, 2002
71. Schwarz ER, Speakman MT, Patterson M, Hale SS, Isner JM, Kedes LH, Kloner RA: Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor (VEGF) in a myocardial infarction model in the rat - Angiogenesis and angioma formation. J Am Coll Cardiol 35: 1323-1330, 2000
72. Lathi KG, Vale PR, Losordo DW, Cespedes RM, Symes JF, Esakof DD, Maysky M, Isner JM: Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease: Anesthetic management and results. Anesth Analg 92: 19-25, 2001